Jenny Marlowe
Chief Development Officer nChroma Bio
Dr. Jenny Marlowe serves as Chief Development Officer of nChroma Bio, bringing extensive expertise in research and development, gene therapy, and translational sciences. She joined nChroma in December 2024, following her role as Chief Development Officer at Chroma Medicine, where she led development efforts through its merger with Nvelop Therapeutics.
Prior to Chroma Medicine, Jenny was Chief Scientific Officer at Solid Biosciences, overseeing R&D efforts for gene therapy programs targeting neuromuscular and genetic cardiomyopathy indications. She also served as Chief Scientific Officer of AavantiBio, where she led scientific strategy until the company’s acquisition by Solid Biosciences.
Seminars
Aligning editing durability with disease specific biological drivers, ensuring long-lasting therapeutic benefit-specific biological drivers
Balancing targeted delivery capabilities with cargo design requirements, maximizing safety and functional persistence
Designing persistence, monitoring, and retreatment frameworks suited to long-term in vivo modulation, enabling reliable patient management over time-term
